Document is current
Any future updates will be listed below
-
Authors
Yao, Douglas https://orcid.org/0000-0002-0939-4670
Binan, Loic
Bezney, Jon
Simonton, Brooke
Freedman, Jahanara
Frangieh, Chris J.
Dey, Kushal https://orcid.org/0000-0002-3520-2345
Geiger-Schuller, Kathryn
Eraslan, Basak
Gusev, Alexander https://orcid.org/0000-0002-7980-4620
Regev, Aviv
Cleary, Brian
-
Funding
Funding for this research was provided by:
National Science Foundation (1745303)
U.S. Department of Health & Human Services | National Institutes of Health (R00HG012203, P30 CA008748, HG006399)
Josie Robertson Investigators Program
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG006193)
Broad Fellows program Merkin Institute Fellowship
- License Information
-
More Information
Article History
Received: 5 January 2023
Accepted: 22 August 2023
First Online: 23 October 2023
Competing interests
: A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and, until 31 July 2020, was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. A.R., B.E. and K.G.-S. are employees of Genentech from 1 August 2020, 10 March 2022 and 16 November 2020, respectively. A.R. and K.G.-S. have equity in Roche. B.C. and A.R. are co-inventors on patents filed by the Broad Institute relating to Perturb-seq and compressed sensing methods as detailed in this paper. The remaining authors declare no competing interests.
